| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PROC |
| Uniprot No | P04070 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 43-461aa |
| 氨基酸序列 | ANSFLEELRHSSLERECIEEICDFEEAKEIFQNVDDTLAFWSKHVDGDQCLVLPLEHPCASLCCGHGTCIDGIGSFSCDCRSGWEGRFCQREVSFLNCSLDNGGCTHYCLEEVGWRRCSCAPGYKLGDDLLQCHPAVKFPCGRPWKRMEKKRSHLKRDTEDQEDQVDPRLIDGKMTRRGDSPWQVVLLDSKKKLACGAVLIHPSWVLTAAHCMDESKKLLVRLGEYDLRRWEKWELDLDIKEVFVHPNYSKSTTDNDIALLHLAQPATLSQTIVPICLPDSGLAERELNQAGQETLVTGWGYHSSREKEAKRNRTFVLNFIKIPVVPHNECSEVMSNMVSENMLCAGILGDRQDACEGDSGGPMVASFHGTWFLVGLVSWGEGCGLLHNYGVYTKVSRYLDWIHGHIRDKEAPQKSWAP |
| 预测分子量 | 54.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组Protein C(PROC)的3篇代表性文献示例，内容基于学术研究背景整理：
---
1. **标题**: *"High-level expression of recombinant human protein C in mammalian cells using a modified vector system"*
**作者**: Yan, S.B., et al.
**摘要**: 研究通过优化哺乳动物细胞表达载体，显著提高了重组人Protein C的产量。文章详细描述了启动子选择、信号肽优化及纯化工艺改进，为规模化生产抗凝血药物提供技术参考。
---
2. **标题**: *"Functional characterization of a novel recombinant protein C variant for anticoagulant therapy"*
**作者**: Smith, J.R., & Johnson, L.M.
**摘要**: 报道了一种新型重组Protein C变体的开发，通过定点突变增强其抗凝血酶活性及稳定性。实验显示该变体在体外模型中有效抑制血栓形成，具有潜在临床转化价值。
---
3. **标题**: *"Escherichia coli-based production of bioactive protein C: challenges and solutions"*
**作者**: Chen, H., et al.
**摘要**: 探讨利用大肠杆菌表达系统生产功能性重组Protein C的技术难点，包括二硫键折叠和γ-羧化修饰问题。提出融合标签策略与体外复性方法，为原核系统生产复杂糖蛋白提供新思路。
---
注：以上文献为示例性质，实际引用时需通过PubMed、Web of Science等平台核对原文信息及DOI编号。重组Protein C研究多聚焦于表达系统优化(如CHO细胞)、功能修饰及治疗应用(如败血症或遗传性缺乏症)。
PROC (Protein C) is a vitamin K-dependent glycoprotein that plays a critical role in regulating blood coagulation and maintaining hemostasis. Naturally synthesized in the liver as an inactive zymogen, it is activated by thrombin-thrombomodulin complexes on endothelial cells. Activated Protein C (APC) exerts anticoagulant effects by proteolytically inactivating coagulation factors Va and VIIIa, while also enhancing fibrinolysis through interactions with plasminogen activator inhibitor-1 (PAI-1). Its deficiency, whether congenital or acquired, is associated with thrombotic disorders such as deep vein thrombosis and purpura fulminans.
Recombinant Protein C (PROC) technology emerged to address therapeutic needs for patients with hereditary Protein C deficiency and other thrombophilic conditions. Developed using genetic engineering, recombinant PROC is produced by inserting the human PROC gene into expression systems like mammalian cells (e.g., CHO or HEK293) to ensure proper post-translational modifications, including γ-carboxylation critical for functional activity. This approach offers advantages over plasma-derived Protein C by eliminating infection risks and enabling scalable production.
Clinically, recombinant PROC has been explored as both a replacement therapy and an anticoagulant agent. Its potential extends to treating sepsis-induced coagulopathy and inflammatory conditions, leveraging APC's cytoprotective and anti-inflammatory properties. Research continues to optimize its pharmacokinetics and reduce bleeding risks through engineered variants. Additionally, recombinant PROC serves as a vital tool for studying thrombosis mechanisms and screening anticoagulant drugs, bridging translational research and therapeutic innovation.
×
